A living drug: application of CAR-T therapy for lymphoid malignancies and beyond

The ongoing development of novel personalized cancer therapies has resulted in the implementation T cells enriched with synthetic chimeric antigen receptors, known as receptors cell (CAR-T) cells, into clinical practice. CAR-T are able to recognize and bind specific antigens present on surface target — so-called tumor-associated antigens. This innovative method been approved for treatment hematological malignancies may also serve a bridge hematopoietic stem transplantation. production drug containing modified consists several steps leukapheresis, activation, transduction expansion final cells. Activation occurs through pathway independent major histocompatibility complex, which is often associated uncontrolled responses from immune system adverse reactions such cytokine release syndrome. therapy can only be performed certified centers, requires close cooperation between experienced specialists different medical disciplines. what determines its effectiveness. Every step collection cryopreservation, transport modification, thawing infusion strictly controlled because it critical impact quality efficiency drug. Despite proven benefits, remains available patients who meet well-defined criteria. These however liable change emergence new indications.